Cristina Truica, MD - Penn State Cancer Institute
Researcher Profile
Cristina Truica, MD
Associate Professor, Department of Medicine
Director of Breast Medical Oncology, Division of Hematology and Oncology
Center for Cannabis and Natural Product Pharmaceuticals (CCNPP)
Director of Breast Medical Oncology, Division of Hematology and Oncology
Center for Cannabis and Natural Product Pharmaceuticals (CCNPP)
Scientific Program:Next-Generation Therapies
Disease Teams:
Cancer Institute, Breast Cancer Team
Clinical Trials
EXActDNA-003: Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated with Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease (NSABP B-64)
General Protocol for the Acquisition of Whole Blood for the Detection and Characterization of Circulating Tumor Cells and/or Tumor Specific Immunity/Immune Cell Activation for any Malignancy at any Stage of Disease
CCTG MA.39:Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer
A012103: OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
NRG-BR009: A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score (OFSET)
Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study
A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant compared with Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients with BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)
NRG-CC015: HARNESSING E-MINDFULNESS APPROACHES FOR LIVING-AFTER BREAST CANCER---HEAL-ABC A Randomized Phase III Trial Testing the Efficacy of Remote Delivery of Mindfulness Awareness Practices in the NCORP; funding to Dr. Julienne Bower, MPI (contact) and Dr. Patricia Ganz, MPI at the University of California, Los Angeles (UCLA).
NRG-BR007: A Phase III Clinical Trial Evaluating Deescalation of Breast Radiation for Conservative Treatment of Stage I, Hormone sensitive, HER2- Negative Oncotype recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence -A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)
Lotam: A Randomized, Phase III Clinical Trial Of Low-Dose Tamoxifen For Selected Patients With Molecular Low-Risk Early-Stage Breast Cancer
An Open Label, Phase II Trial of Pre-operative Neratinib and Endocrine Therapy with Trastuzumab in Triple Positive Breast Cancers
A Phase II Study of Ribociclib and Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study) (HCRN-BRE20-468)
EXActDNA-003: Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated with Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease (NSABP B-64)
Recent Publications
2024
Derbes, R, Hakun, J, Elbich, D, Master, L, Berenbaum, S, Huang, X, Buxton, OM, Chang, AM, Truica, CI & Sturgeon, KM 2024, 'Design and methods of the mobile assessment of cognition, environment, and sleep (MACES) feasibility study in newly diagnosed breast cancer patients', Scientific reports, vol. 14, no. 1, 8338. https://doi.org/10.1038/s41598-024-58724-1
2023
Bluethmann, SM, Flores, E, Grotte, M, Heitzenrater, J, Truica, CI, Olsen, NJ, Sciamanna, C & Schmitz, KH 2023, 'Adapting an Evidence-Based Exercise and Education Program for Older Breast Cancer Survivors for the REJOIN Trial', Journal of Aging and Physical Activity, vol. 31, no. 1, pp. 59-67. https://doi.org/10.1123/japa.2022-0013
Gordon, BR, Qiu, L, Doerksen, SE, Kanski, B, Lorenzo, A, Truica, CI, Vasekar, M, Wang, M, Winkels, RM, Abdullah, S & Schmitz, KH 2023, 'Addressing metastatic individuals everyday: Rationale and design of the nurse AMIE for Amazon Echo Show trial among metastatic breast cancer patients', Contemporary Clinical Trials Communications, vol. 32, 101058. https://doi.org/10.1016/j.conctc.2023.101058
Schmitz, KH, Kanski, B, Gordon, B, Caru, M, Vasakar, M, Truica, CI, Wang, M, Doerksen, S, Lorenzo, A, Winkels, R, Qiu, L & Abdullah, S 2023, 'Technology-based supportive care for metastatic breast cancer patients', Supportive Care in Cancer, vol. 31, no. 7, 401. https://doi.org/10.1007/s00520-023-07884-3
Caru, M, Abdullah, S, Qiu, L, Kanski, B, Gordon, B, Truica, CI, Vasakar, M, Doerksen, S & Schmitz, KH 2023, 'Women with metastatic breast cancer don't just follow step-count trends, they exceed them: an exploratory study', Breast Cancer Research and Treatment, vol. 200, no. 2, pp. 265-270. https://doi.org/10.1007/s10549-023-06980-6
2022
Teslenko, I, Trudeau, J, Luo, S, Watson, CJW, Chen, G, Truica, CI & Lazarus, P 2022, 'Influence of Glutathione-S-Transferase A1*B Allele on the Metabolism of the Aromatase Inhibitor, Exemestane, in Human Liver Cytosols and in Patients Treated with Exemestane', Journal of Pharmacology and Experimental Therapeutics, vol. 382, no. 3, pp. 327-334. https://doi.org/10.1124/jpet.122.001232